CONTINUING prostate-specific antigen (PSA) screening into older age leads to more overdiagnoses relative to prostate cancer deaths prevented, particularly among men with severe comorbidities, a modelling study suggests.
The analysis found that modern screening approaches could improve the balance of harms and benefits. However, higher PSA thresholds and MRI-based investigation did not remove the growing disadvantage associated with advancing age and life-limiting illness.
Modelling Screening Beyond 70
Researchers used two independently developed microsimulation models from the Fred Hutch Cancer Center and the University of Michigan, USA, to estimate lifetime outcomes of continued screening.
The simulated men had undergone screening every 2 years between ages 50 and 70 and remained without a prostate cancer diagnosis at age 72. Outcomes were assessed across groups with no, mild, moderate, or severe comorbidities, using previously estimated differences in survival from causes other than cancer.
The models examined continued screening at ages 72, 74, and 76. Strategies included raising the PSA threshold for further investigation from 3.0 to 6.5 ng/mL, with MRI followed by targeted biopsy when indicated. Another approach also stopped screening in men whose PSA fell below 3.0 ng/mL from age 70 onwards.
Greater Harm Relative to Benefit
Using the 6.5 ng/mL threshold, the estimated number of overdiagnoses per prostate cancer death prevented increased with age.
Among men without comorbidities, this ratio rose from 2.7–3.1 at age 72 to 4.5–5.1 at age 76. For men with severe comorbidities, the corresponding estimates were 9.6–10.2 and 11.3–12.6.
Overdiagnosis was defined as a cancer diagnosis that would not have occurred during a man’s lifetime without screening. Such diagnoses can expose patients to further investigations and potentially unnecessary treatment.
Raising the investigation threshold reduced both overdiagnosis and screening benefit. At age 72, moving from 3.0 to 6.5 ng/mL reduced estimated overdiagnoses by 60–68% among men without comorbidities, while reducing cancer deaths prevented by 26–35%.
Stopping screening in men with low PSA levels substantially reduced testing, but produced similar ratios of overdiagnoses to deaths prevented.
Supporting Individual Decisions
The findings support considering comorbidity and life expectancy alongside age when discussing whether to continue screening. The authors conclude that continued screening should be limited to selected older men with sufficient life expectancy, few life-limiting conditions, and an informed preference for testing.
However, these are modelled estimates rather than outcomes observed in a new clinical trial. Assumptions about cancer progression, diagnostic performance, and survival introduce uncertainty, particularly around absolute numbers.
Both models nevertheless showed consistent trends, suggesting that modern diagnostic pathways improve screening trade-offs without eliminating the need for careful decisions about when to stop.
Reference
Gulati R et al. Estimated lifetime harms and benefits of continuing biennial prostate cancer screening in older men by comorbidity group. Cancer. 2026;e70620. doi:10.1002/cncr.70620.